BCIQ Profiles

Company Profile ReportTarget Profile Report
0818 Immunitas
BioCentury & Getty Images

Emerging Company Profile

Immunitas: Strategics back $58M B round to push CD161 inhibitor into the clinic

Emerging Company Profile: First-in-class immuno-oncology therapy from Boston single cell genomics play attracts 16 investors

First-in-class immuno-oncology therapy from Boston single cell genomics play Immunitas attracts 16 investors, giving the biotech funds to reach the clinic next year.

Aug 18, 2021 | 10:02 PM GMT

With a $58 million B round in hand from a swath of new investors, Immunitas is aiming to push its first-in-class CD161 inhibitor

Read the full 825 word article

How to gain access

Continue reading with a
two-week free trial.